Induction of robust cellular immunity against HPV6 and HPV11 in mice by DNA vaccine encoding for E6/E7 antigen

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 4, 2012, Pages 470-478

  Shin, Thomas H ^a   Pankhong, Panyupa ^a   Yan, Jian ^b   Khan, Amir S ^b   Sardesai, Niranjan Y ^b   Weiner, David B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Inovio Pharmaceuticals Inc   (United States)

Author keywords

DNA vaccine; E6 E7; Electroporation; HPV11; HPV6; Human papillomavirus

Indexed keywords

ANTIGEN; CYTOKINE; DNA VACCINE; EPITOPE; GAMMA INTERFERON; HYBRID PROTEIN; PLASMID DNA; PROTEIN E6; PROTEIN E7; RNA; SIGNAL PEPTIDE; TUMOR NECROSIS FACTOR ALPHA; ONCOPROTEIN; RECOMBINANT VACCINE; VIRUS ANTIGEN; WART VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CANCER RISK; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CODON; CONSENSUS SEQUENCE; CONTROLLED STUDY; CYTOKINE RELEASE; DNA IMMUNIZATION; EPITOPE MAPPING; FEMALE; GENE CONSTRUCT; GENE EXPRESSION; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOFLUORESCENCE; IMMUNOGENICITY; MOUSE; NONHUMAN; PROTEIN FOLDING; STAINING; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; GENETICS; IMMUNOLOGY;

ANIMALS; ANTIGENS, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; EPITOPE MAPPING; EPITOPES, T-LYMPHOCYTE; FEMALE; HUMAN PAPILLOMAVIRUS 11; HUMAN PAPILLOMAVIRUS 6; INTERFERON-GAMMA; MICE; MICE, INBRED C57BL; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS VACCINES; RECOMBINANT FUSION PROTEINS; TUMOR NECROSIS FACTOR-ALPHA; VACCINES, DNA; VACCINES, SYNTHETIC;

EID: 84860717987     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.19180     Document Type: Article

References (27)

1. WHO/ICO HPV Information Centre. Human Papillomavirus and Related Cancers in World. Summary Report 2010. WHO. [www.who.int/hpvcentre] Accessed on 8 July 2011
2. Muñoz N, Bosch FX, Castellsagué X, Díaz M, de Sanjose S, Hammouda D, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004; 111:278-85; PMID:15197783; http://dx.doi.org/10.1002/ijc.20244.
3. Lin HW, Richmon JD, Emerick KS, de Venecia RK, Zeitels SM, Faquin WC, et al. Malignant transformation of a highly aggressive human papillomavirus type 11-associated recurrent respiratory papillomatosis. Am J Otolaryngol 2010; 31:291-6; PMID:20015762; http://dx.doi.org/10.1016/j.amjoto.2009.02.019.
4. Bonagura VR, Hatam LJ, Rosenthal DW, de Voti JA, Lam F, Steinberg BM, et al. Recurrent respiratory papillomatosis: a complex defect in immune responsiveness to human papillomavirus-6 and -11. APMIS 2010; 118:455-70; PMID:20553528; http://dx.doi.org/10.1111/j.1600-0463.2010.02617.x.
5. Donne AJ, Hampson L, Homer JJ, Hampson IN. The role of HPV type in Recurrent Respiratory Papillomatosis. Int J Pediatr Otorhinolaryngol 2010; 74:7-14; PMID:19800138; http://dx.doi.org/10.1016/j.ijporl.2009.09.004.
6. Combita AL, Touzé A, Bousarghin L, Christensen ND, Coursaget P. Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J Virol 2002; 76:6480-6; PMID:12050360; http://dx.doi.org/10.1128/JVI.76.13.6480-6.2002.
7. Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, et al.; Costa Rican HPV Vaccine Trial Group. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007; 298:743-53; PMID:17699008; http://dx.doi.org/10.1001/jama.298.7.743.
8. Lin K, Roosinovich E, Ma B, Hung CF, Wu TC. Therapeutic HPV DNA vaccines. Immunol Res 2010; 47:86-112; PMID:20066511; http://dx.doi.org/10.1007/s12026- 009-8141-6.
9. Gissmann L. HPV vaccines: preclinical development. Arch Med Res 2009; 40:466-70; PMID:19853186; http://dx.doi.org/10.1016/j.arcmed.2009.07.002.
10. Kanodia S, Da Silva DM, Kast WM. Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. Int J Cancer 2008; 122:247-59; PMID:17973257; http://dx.doi.org/10.1002/ijc.23252.
11. Santin AD, Bellone S, Palmieri M, Zanolini A, Ravaggi A, Siegel ER, et al. Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. J Virol 2008; 82:1968-79; PMID:18057249; http://dx.doi.org/10.1128/JVI.02343-07.
12. Yan J, Harris K, Khan AS, Draghia-Akli R, Sewell D, Weiner DB. Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6/E7 fusion consensus protein in mice and rhesus macaques. Vaccine 2008; 26:5210-5; PMID:18455277; http://dx.doi.org/10.1016/j.vaccine.2008.03.069.
13. Yan J, Reichenbach DK, Corbitt N, Hokey DA, Ramanathan MP, McKinney KA, et al. Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen. Vaccine 2009; 27:431-40; PMID:19022315; http://dx.doi.org/10.1016/j.vaccine.2008.10.078.
14. Kim D, Hoory T, Monie A, Ting JP, Hung CF, Wu TC. Enhancement of DNA vaccine potency through coadministration of CIITA DNA with DNA vaccines via gene gun. J Immunol 2008; 180:7019-27; PMID:18453624.
15. +T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine 2009; 27:5450-9; PMID:19622402; http://dx.doi.org/10.1016/j.vaccine.2009.07.005.
16. Tseng CW, Trimble C, Zeng Q, Monie A, Alvarez RD, Huh WK, et al. Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts. Cancer Immunol Immunother 2009; 58:737-48; PMID:18815785; http://dx.doi.org/10. 1007/s00262-008-0596-0.
17. + T cell responses and therapeutic antitumor effect by antigen engineering and electroporation. Vaccine 2009; 27:5906-12; PMID:19651174; http://dx.doi.org/10.1016/j.vaccine.2009.07.033.
18. Ohlschläger P, Quetting M, Alvarez G, Dürst M, Gissmann L, Kaufmann AM. Enhancement of immunogenicity of a therapeutic cervical cancer DNA-based vaccine by co-application of sequence-optimized genetic adjuvants. Int J Cancer 2009; 125:189-98; PMID:19358269; http://dx.doi.org/10.1002/ijc.24333.
19. Trimble CL, Peng S, Kos F, Gravitt P, Viscidi R, Sugar E, et al. A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res 2009; 15:361-7; PMID:19118066; http://dx.doi.org/10.1158/1078-0432.CCR-08-1725.
20. Wu A, Zeng Q, Kang TH, Peng S, Roosinovich E, Pai SI, et al. Innovative DNA vaccine for human papillomavirus (HPV)-associated head and neck cancer. Gene Ther 2011; 18:304-12; PMID:20981112; http://dx.doi.org/10.1038/gt.2010.151.
21. + T-cell immune responses leading to therapeutic antitumor effects. Gene Ther 2008; 15:1156-66; PMID:18401437; http://dx.doi.org/10.1038/gt.2008.53.
22. Huang CF, Monie A, Weng WH, Wu T. DNA vaccines for cervical cancer. Am J Transl Res 2010; 2:75-87; PMID:20182584.
23. Morrow MP, Pankhong P, Laddy DJ, Schoenly KA, Yan J, Cisper N, et al. Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood 2009; 113:5868-77; PMID:19304955; http://dx.doi.org/10.1182/blood-2008-11-190520.
24. Morrow MP, Yan J, Pankhong P, Shedlock DJ, Lewis MG, Talbott K, et al. IL-28B/IFN-lambda 3 drives granzyme B loading and significantly increases CTL killing activity in macaques. Mol Ther 2010; 18:1714-23; PMID:20571540; http://dx.doi.org/10.1038/mt.2010.118.
25. Bonnez W. Papilloma Virus. In: Richman D, Whitley R, Hayden F, Eds. Clinical Virology. Washington DC: American Society for Microbiology Press 2002; 2:557-96.
26. Peng S, Best SR, Hung CF, Loyo M, Lyford-Pike S, Flint PW, et al. Characterization of human papillomavirus type 11-specific immune responses in a preclinical model. Laryngoscope 2010; 120:504-10; PMID:20025042; http://dx.doi.org/10.1002/lary.20745.
27. Jeong WJ, Park SW, Shin M, Lee YJ, Jeon YK, Jung YH, et al. Presence of HPV type 6 in dysplasia and carcinoma arising from recurrent respiratory papillomatosis. Head Neck 2009; 31:1095-101; PMID:19072996; http://dx.doi.org/ 10.1002/hed.20998.